Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 5, 2008, Pages 625-629

  Piao, Yong Ji ^a   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; GLYCOPROTEIN P; MORIN; NICARDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FLAVONOIDS; INJECTIONS, INTRAVENOUS; MALE; NICARDIPINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 42549117615     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.5.0008     Document Type: Article

References (23)

1. Choi, B. C., Choi, J. S., Han, H. K. (2006) Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int. J. Pharm. 323: 81-85
2. Choi, J. S., Burm, J. P. (2006) Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Arch. Pharm. Res. 29: 333-338
3. Choi, J. S., Han, H. K. (2005) Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol. Res. 52: 386-391
4. Eastwood, R. J., Galustian, C., Bhamra, R. K., Holt, D. W. (1990) High-performance liquid chromatographic method for the measurement of nicardipine in plasma or serum. J. Chromatogr. 530: 463-468
5. Graham, D. J., Dow, R. J., Freedman, D., Mroszczak, E., Ling, T. (1984) Pharmacokinetics of nicardipine following oral and intravenous administration in man. Postgrad. Med. J. 4: 7-10
6. Graham, D. J., Dow, R. J., Hall, D. J., Alexander, O. F., Mroszczak, E. J., Freedman, D. (1985) The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br. J. Clin. Pharmacol. 1: 23-28
7. Guengerich, F. P. (1991) Reactions and significance of cytochrome P-450 enzymes. J. Biol. Chem. 266: 10 019-10 022
8. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., Waxman, D. J. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261: 5051-5060
9. Higuchi, S., Shiobara, Y. (1980) Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 10: 889-896
10. Hodek, P., Trefil, P., Stiborova, M. (2002) Flavonoids - potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139: 1-21
11. Hou, Y. C., Chao, P. D., Ho, H. J., Wen, C. C., Hsiu, S. L. (2003) Profound difference in pharmacokinetics between morin and its isomer quercetin in rats. J. Pharm. Pharmacol. 55: 199-203
12. Hsiu, S. L., Tsao, C. W., Tsai, Y. C., Ho, H. J., Chao, P. D. (2001) Determinations of morin, quercetin and their conjugate metabolites in serum. Biol. Pharm. Bull. 24: 967-969
13. Hu, Y. P., Chapey, C., Robert, J. (1996) Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Lett. 109: 203-209
14. Hysing, E. S., Chelly, J. E., Doursout, M. F., Hartley, C., Merin, R. G. (1986) Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. III. Nicardipine and isoflurane. Anaesthesiology 65: 385-391
15. Kishi, Y., Okumura, F., Furuya, H. (1984) Haemodynamic effects of nicardipine hydrochloride. Studies during its use to control acute hypertension in anaesthetized patients. Br. J. Anaesth. 56: 1003-1007
16. Kitagawa, S., Nabekura, T., Takahashi, T., Nakamura, Y., Sakamoto, H., Tano, H., Hirai, M., Tsukahara, G. (2005) Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol. Pharm. Bull. 28: 2274-2278
17. Middleton, E. Jr, Kandaswami, C., Theoharides, T. C. (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol. Rev. 52:673-751
18. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Romano, T. (1993) P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324: 99-102
19. Shin, S. C., Choi, J. S., Li, X. (2006) Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Inter. J. Pharm. 313: 144-149
20. Van Zwieten, P. A., Hansson, L., Epstein, M. (1997) Slowly acting calcium antagonists and their merits. Blood Press. 6: 78-80
21. Wacher, V. J., Salphati, L., Benet, L. Z. (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46: 89-102
22. Wang, E. J., Casciano C. N., Clement, R. P., Johnson, W. W. (2000) Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim. Biophys. Acta. 1481: 63-74
23. Zhang, S., Morris, M. E. (2003) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther. 304: 1258-1267